by Plus Therapeutics | Mar 13, 2024 | Uncategorized
AVAILABLE NOW: The new Plus Therapeutics corporate presentation, which reflects our current data, milestones, and pipeline, is on our website. View it directly here: https://bit.ly/3PiHClj Questions about anything or interested in learning more? Visit our website at...
by Plus Therapeutics | Mar 11, 2024 | LM
BREAKING NEWS! We have completed dosing in Cohort 5 of our ongoing ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases, with a total of 18 patients have been dosed in the trial to date. The trial is STILL ENROLLING and accepting new...
by Plus Therapeutics | Mar 7, 2024 | Uncategorized
We are thrilled to announce our sponsorship with @glioblastomaresearch this upcoming season on their “Glioblastoma AKA GBM” podcast! 🧠 We appreciate their goal of raising awareness and funds for new global, cutting-edge research to find a cure for...
by Plus Therapeutics | Mar 6, 2024 | LM
Some of our clinical team will be attending the #MiamiBreast Cancer Conference this week, as it relates to our Leptomeningeal Metastases clinical trial for Metastatic Breast Cancer patients. If you are interested in connecting with the team there, send us a DM. See...
by Plus Therapeutics | Feb 29, 2024 | Uncategorized
Today on leap day, the rarest day of the year, we celebrate Rare Disease Day along with the NIH and other organizations. Plus Therapeutics is dedicated to developing innovative, targeted radiotherapeutics for adult & pediatric patients with rare &...
Recent Comments